TY - JOUR
T1 - A discrete-choice experiment study of physicians’ prioritization of attributes of medical treatments for endometriosis-associated pain
AU - Poulos, Christine
AU - Xu, Yanqing
AU - Botha, Willings
AU - Leach, Colton
AU - Wrobleski, Kristin Kahle
AU - Gordon, Keith
AU - Missmer, Stacey A.
AU - Estes, Stephanie J.
N1 - Funding Information:
C Poulos and C Leach are full-time employees of RTI Health Solutions, an independent nonprofit research organization, which was retained by AbbVie to conduct the research which is the subject of this manuscript. Their compensation is unconnected to the studies on which they work. W Botha is a past employee of RTI Health Solutions. Y Xu is an employee of AbbVie and may hold shares and/or stock options in the company. K Kahle-Wrobleski was a past employee of AbbVie and may hold shares and/or stock options in the company; she is now employed by GSK. K Gordon was a past employee of AbbVie and may hold shares and/or stock options in the company; he is now employed by Organon. S Estes is an employee of Penn State Health, has received research funding from AbbVie, Ferring, and Obseva, and is a consultant for AbbVie and Upsilon. S Missmer is an employee of Michigan State University and has been an advisory board member for AbbVie and Roche and receives research funding from the National Institutes of Health, the Department of Defense, the J. Willard and Alice S. Marriott Foundation, and AbbVie. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Publisher Copyright:
© 2022 RTI Health Solutions Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023
Y1 - 2023
N2 - Background: Physicians’ preferences for attributes of medical treatments for endometriosis-associated pain have not previously been quantified. Methods: US obstetrician-gynecologists completed an online discrete-choice experiment survey. In a series of questions, physicians chose a medical treatment for a hypothetical patient with endometriosis experiencing severe, persistent dysmenorrhea, nonmenstrual pelvic pain, and/or dyspareunia. Each question presented two hypothetical medical treatments for endometriosis-associated pain, defined by seven attributes with varying levels. Preferences weights and conditional relative importance (CRI) were calculated using a random-parameters logit model. Results: Respondents (N = 250) had an average age of 53 years; 36% were female. The most important attribute, conditional on the attributes and levels evaluated, was risk of moderate-to-severe hot flashes (CRI, 3.34). In descending order of importance, the CRIs of the other attributes were 2.13 for improvement in nonmenstrual pelvic pain, 2.04 for improvement in dyspareunia, 1.88 for improvement in dysmenorrhea, 1.16 for risk of pregnancy-related complications if pregnancy occurs during treatment, 0.62 for increased risk of bone fracture later in life, and 0.48 for mode of administration. Conclusions: In addition to valuing pain reduction, respondents prioritized avoiding moderate-to-severe hot flashes, followed by less common and less immediate risks of pregnancy-related complications and bone fracture.
AB - Background: Physicians’ preferences for attributes of medical treatments for endometriosis-associated pain have not previously been quantified. Methods: US obstetrician-gynecologists completed an online discrete-choice experiment survey. In a series of questions, physicians chose a medical treatment for a hypothetical patient with endometriosis experiencing severe, persistent dysmenorrhea, nonmenstrual pelvic pain, and/or dyspareunia. Each question presented two hypothetical medical treatments for endometriosis-associated pain, defined by seven attributes with varying levels. Preferences weights and conditional relative importance (CRI) were calculated using a random-parameters logit model. Results: Respondents (N = 250) had an average age of 53 years; 36% were female. The most important attribute, conditional on the attributes and levels evaluated, was risk of moderate-to-severe hot flashes (CRI, 3.34). In descending order of importance, the CRIs of the other attributes were 2.13 for improvement in nonmenstrual pelvic pain, 2.04 for improvement in dyspareunia, 1.88 for improvement in dysmenorrhea, 1.16 for risk of pregnancy-related complications if pregnancy occurs during treatment, 0.62 for increased risk of bone fracture later in life, and 0.48 for mode of administration. Conclusions: In addition to valuing pain reduction, respondents prioritized avoiding moderate-to-severe hot flashes, followed by less common and less immediate risks of pregnancy-related complications and bone fracture.
UR - http://www.scopus.com/inward/record.url?scp=85146231817&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146231817&partnerID=8YFLogxK
U2 - 10.1080/14737167.2023.2152006
DO - 10.1080/14737167.2023.2152006
M3 - Article
C2 - 36625547
AN - SCOPUS:85146231817
SN - 1473-7167
VL - 23
SP - 111
EP - 121
JO - Expert Review of Pharmacoeconomics and Outcomes Research
JF - Expert Review of Pharmacoeconomics and Outcomes Research
IS - 1
ER -